PRA recently opened a new office in Bucharest, Romania to further strengthen its coverage of the Balkan region’s burgeoning markets. The Bucharest office will also support projects in the neighboring Republic of Moldova.
Since 2006, when PRA began conducting clinical trials in Romania, the PRA staff has steadily increased and now includes both product registration and early phase professionals. The number of studies initiated by PRA in this region has more than doubled over the last two years.
“By being based in the Balkan region’s key business and life sciences hub, the Bucharest staff has convenient access to top universities, academic research sites, and most of the country’s major hospitals,” said Ludger Langer, PRA’s Vice President of Clinical Operations in Europe, Asia-Pacific and Africa.
The Bucharest location is the 12th office PRA has opened worldwide since 2009, demonstrating its commitment to meeting its clients’ diverse needs in a dynamic clinical trials environment.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
FDA Fast Tracks Johnson & Johnson’s Nipocalimab for Fetal Neonatal Alloimmune Thrombocytopenia
March 27th 2024Johnson & Johnson is moving forward with a pair of Phase III trials of nipocalimab to reduce the risk of fetal neonatal alloimmune thrombocytopenia in alloimmunized pregnant patients.